Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
It is indicated for the treatment of early-stage and advanced-stage HER2-positive breast cancer, and can be used as a monotherapy for adjuvant treatment or in combination with cape···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is indicated for the treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung disease (ILD), and systemic sclerosis-associated interstitial lung dis···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：11
It is indicated for the treatment of relapsed or refractory acute leukemia (with KMT2A translocation) or relapsed or refractory acute myeloid leukemia (with NPM1 mutation) in adult···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：7
It is indicated for the treatment of cholestatic pruritus in patients aged 3 months and older with progressive familial intrahepatic cholestasis (PFIC) and patients aged 12 months ···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary myelofibrosis and a platelet count of less than 50 × 10⁹/L.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：7
On July 22, 2021, Merck & Co., Inc. and Eisai Co., Ltd. jointly announced that the U.S. Food and Drug Administration (FDA) had approved Merck’s anti-PD-1 therapy pembrolizumab ···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：22
Merck & Co., Inc. and Eisai Co., Ltd. jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 therapy pembrolizumab in combinati···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：19
Ivosidenib is mainly metabolized by the CYP3A4 enzyme. Co-administration with drugs that affect the activity of this enzyme may significantly alter the plasma concentration of ivos···【more】
Article source：Captain MedicineRelease date：2026-01-04Recommended：46
Ivosidenib has interactions with a variety of drugs, which may affect its efficacy or increase the risk of adverse reactions. Close monitoring and dosage adjustment are required wh···【more】
Article source：Captain MedicineRelease date：2026-01-04Recommended：29
Ivosidenib is indicated only for patients with acute myeloid leukemia (AML), cholangiocarcinoma, or myelodysplastic syndromes (MDS) whose tumors harbor an isocitrate dehydrogenase-···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：41
Some side effects usually do not require medical treatment and may resolve on their own as your body gradually adjusts to the medication.How severe are the side effects of Ivosiden···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：28
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：612025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：752025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
